PharmaEssentia Corporation
PharmaEssentia Corporation is a growing biopharmaceutical innovator leveraging expertise and proven scientific principles to deliver effective new biologics for challenging hematologic diseases. Our focus is on therapies for myeloproliferative neoplasms (MPNs), with a product already approved in Europe and a diversifying pipeline. Founded in 2003 by a team of Taiwanese-American executives and renowned scientists, today we are expanding our global presence with operations in the U.S., Japan, China, and Korea, and a world-class biologics production facility in Taichung.